Osteopontin as a Prognostic Marker in Early-Stage Non-Small-Cell Lung Cancer
Author Information
Author(s): Boldrini L, Donati V, Dell'Omodarme M, Prati M C, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G
Primary Institution: University of Pisa
Hypothesis
The study aims to evaluate if osteopontin (OPN) might be involved in the biology of non-small-cell lung cancer (NSCLC) and represent a prognostic marker.
Conclusion
High osteopontin expression is a significantly unfavourable prognostic factor for the survival of patients with stage I non-small-cell lung cancer.
Supporting Evidence
- High OPN expression was found in 47.8% of cases.
- Patients with high OPN expression had shorter overall survival.
- Statistical analysis showed significant correlations between OPN expression and survival outcomes.
- OPN expression was significantly correlated with tumor grade and sex.
- Patients with poorly differentiated tumors showed lower OPN expression.
Takeaway
This study found that a protein called osteopontin can help predict how well patients with early lung cancer will do after treatment.
Methodology
Immunohistochemistry was used to detect OPN expression in tumor samples from 136 patients with stage I NSCLC.
Potential Biases
Potential bias due to the retrospective nature of the study and the selection of patients.
Limitations
The study had an imbalance in the number of male and female participants, which may affect the generalizability of the results.
Participant Demographics
The cohort included 126 male (92.6%) and 10 female (7.4%) patients, with a median age of 66 years.
Statistical Information
P-Value
P=0.034 for overall survival, P=0.011 for disease-free survival
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website